Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors
EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
18
Participants
Timeline
Start Date
February 15, 2025
Primary Completion Date
March 1, 2026
Study Completion Date
March 1, 2027
Conditions
Relapsed or Refractory Hematological Malignancies
Interventions
BIOLOGICAL
JY306 universal NK cell injection
"3+3 dose escalation trial"
All Listed Sponsors
lead
The First Affiliated Hospital with Nanjing Medical University
OTHER
NCT06837389 - Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors | Biotech Hunter | Biotech Hunter